Website
News25/Ratings12
News · 26 weeks77-88%
2025-10-262026-04-19
Mix5690d
- Insider39(70%)
- Other8(14%)
- SEC Filings5(9%)
- Earnings2(4%)
- Leadership1(2%)
- Analyst1(2%)
Latest news
25 items- PRAptar Declares Quarterly DividendAptarGroup, Inc. (NYSE:ATR), a global leader in drug delivery, including dosing and protection technologies, and consumer product dispensing, today announced that the Board declared a quarterly cash dividend of $0.48 per share. The payment date is May 27, 2026, to stockholders of record as of May 6, 2026. As previously announced, Aptar will hold a conference call on Friday, May 1, 2026, at 8:00 a.m. Central Time to discuss the Company's first quarter results for 2026. The call will last approximately one hour. Interested parties are invited to listen to a live webcast by visiting the Investors page at www.aptar.com. A replay of the conference call can also be accessed for a limited time o
- PRAptar Recognized as One of America's Climate Leaders by USA Today for the Fourth Consecutive YearAptarGroup, Inc. (NYSE:ATR), a global leader in drug delivery, including dosing and protection technologies, and consumer product dispensing, announced today that has been named one of America's Climate Leaders by USA Today for the fourth consecutive year. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260422480656/en/Aptar Recognized as One of America's Climate Leaders by USA Today for the Fourth Consecutive Year (Logo used with permission from Statista) "This recognition reflects the dedication of our teams worldwide and our long-term commitment to sustainability and climate action," said Beth Holland, Chief Sustainability Off
- PRAptar Digital Health Partners with Enable Injections for enFuse® Companion Digital SolutionCINCINNATI, April 08, 2026 (GLOBE NEWSWIRE) -- Aptar Digital Health, a global leader in digital health solutions enhancing the patient experience, and Enable Injections, Inc. ("Enable"), a healthcare innovation company developing and manufacturing the enFuse® On-Body Delivery System, today announced a strategic partnership naming Aptar Digital Health as Enable's preferred digital health partner for the enFuse® system. This digital solution will be designed to guide patients and caregivers throughout the injection process and help strengthen engagement support before, during and after administration. Through this partnership, Aptar Digital Health will deliver a companion digital solution
- PRAptar Digital Health Partners with Enable Injections for enFuse® Companion Digital SolutionDigital solution will be designed to help guide users through injection process Aptar Digital Health, a global leader in digital health solutions enhancing the patient experience, and Enable Injections, Inc. ("Enable"), a healthcare innovation company developing and manufacturing the enFuse® On-Body Delivery System, today announced a strategic partnership naming Aptar Digital Health as Enable's preferred digital health partner for the enFuse® system. This digital solution will be designed to guide patients and caregivers throughout the injection process and help support engagement before, during, and after administration. This press release features multimedia. View the full release here
- SECSEC Form DEFA14A filed by AptarGroup Inc.DEFA14A - APTARGROUP, INC. (0000896622) (Filer)
- SECSEC Form DEF 14A filed by AptarGroup Inc.DEF 14A - APTARGROUP, INC. (0000896622) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by AptarGroup Inc.SCHEDULE 13G/A - APTARGROUP, INC. (0000896622) (Subject)
- INSIDERSEC Form 4 filed by Tlili Hedi4 - APTARGROUP, INC. (0000896622) (Issuer)
- INSIDERSEC Form 4 filed by Kanu Vanessa4 - APTARGROUP, INC. (0000896622) (Issuer)
- ANALYSTAptarGroup upgraded by Wells Fargo with a new price targetWells Fargo upgraded AptarGroup from Equal Weight to Overweight and set a new price target of $144.00
- INSIDERSEC Form 4 filed by Tanda Stephan B.4 - APTARGROUP, INC. (0000896622) (Issuer)
- INSIDERSEC Form 4 filed by Ackerman Daniel4 - APTARGROUP, INC. (0000896622) (Issuer)
- INSIDERSEC Form 4 filed by Vinczeller Shiela4 - APTARGROUP, INC. (0000896622) (Issuer)
- INSIDERSEC Form 4 filed by Gong Xiangwei4 - APTARGROUP, INC. (0000896622) (Issuer)
- INSIDERSEC Form 4 filed by Hudson Irene Elizabeth4 - APTARGROUP, INC. (0000896622) (Issuer)
- INSIDERSEC Form 4 filed by Tlili Hedi4 - APTARGROUP, INC. (0000896622) (Issuer)
- INSIDERSEC Form 4 filed by Touya Gael4 - APTARGROUP, INC. (0000896622) (Issuer)
- INSIDERSEC Form 4 filed by Kanu Vanessa4 - APTARGROUP, INC. (0000896622) (Issuer)
- INSIDERSEC Form 4 filed by Prieur Marc4 - APTARGROUP, INC. (0000896622) (Issuer)
- PRAptar's Unidose Powder Nasal Delivery System Used in ENA Respiratory Phase II Clinical Study of Investigational INNA‑051 Nasal SprayUse of Aptar Pharma's UDS Powder system supports the development of a next‑generation, virus‑agnostic nasal spray being evaluated for its potential to help protect against symptomatic viral respiratory infections AptarGroup, Inc. (NYSE:ATR), a global leader in drug delivery, dosing and protection technologies, and consumer product dispensing, today announced that its Unidose (UDS) Powder Nasal Spray System is being utilized in ENA Respiratory's Phase II clinical study of INNA 051, an investigational nasal spray being evaluated for its potential to help protect against symptomatic viral respiratory infections. This collaboration reflects the growing role of intranasal delivery technologies
- INSIDERSEC Form 4 filed by Gong Xiangwei4 - APTARGROUP, INC. (0000896622) (Issuer)
- INSIDERSEC Form 4 filed by Tlili Hedi4 - APTARGROUP, INC. (0000896622) (Issuer)
- INSIDERSEC Form 4 filed by Touya Gael4 - APTARGROUP, INC. (0000896622) (Issuer)
- INSIDERSEC Form 4 filed by Kanu Vanessa4 - APTARGROUP, INC. (0000896622) (Issuer)
- INSIDERSEC Form 4 filed by Hudson Irene Elizabeth4 - APTARGROUP, INC. (0000896622) (Issuer)